Literature DB >> 20058168

Proteomic analysis of protein phosphorylation and ubiquitination in Alzheimer's disease.

Stefani N Thomas1, Diane Cripps, Austin J Yang.   

Abstract

Posttranslational modifications such as phosphorylation and ubiquitination serve, independently or together, as gatekeepers of protein transport and turnover in normal and disease physiologies. Aberrant protein phosphorylation is one of the defining pathological hallmarks of more than 20 different neurodegenerative disorders, including Alzheimer's disease (AD). The disruption of the phosphorylation of neurotransmitter receptors has been implicated as one of the causal factors of impaired memory function in AD (1-3). Another feature of AD is the aberrant accumulation of proteins that are normally degraded by the ubiquitin proteasome system upon being conjugated to ubiquitin. Thus, elucidating the protein targets of phosphorylation and ubiquitination that can serve as AD biomarkers will aid in the development of effective therapeutic approaches to the treatment of AD. This chapter provides details pertaining to the qualitative and quantitative liquid chromatography tandem mass spectrometry-based analysis of an affinity purified, phosphorylated, and ubiquitinated protein, paired-helical filament tau.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20058168      PMCID: PMC4708882          DOI: 10.1007/978-1-59745-562-6_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  29 in total

1.  Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system.

Authors:  J Y Zhang; S J Liu; H L Li; J-Z Wang
Journal:  J Neural Transm (Vienna)       Date:  2004-09-14       Impact factor: 3.575

Review 2.  Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease.

Authors:  K Iqbal; I Grundke-Iqbal
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

3.  Optimization of mass spectrometry-compatible surfactants for shotgun proteomics.

Authors:  Emily I Chen; Daniel Cociorva; Jeremy L Norris; John R Yates
Journal:  J Proteome Res       Date:  2007-05-27       Impact factor: 4.466

4.  Conformational change as one of the earliest alterations of tau in Alzheimer's disease.

Authors:  C L Weaver; M Espinoza; Y Kress; P Davies
Journal:  Neurobiol Aging       Date:  2000 Sep-Oct       Impact factor: 4.673

Review 5.  Post-translational modifications of tau protein in Alzheimer's disease.

Authors:  C-X Gong; F Liu; I Grundke-Iqbal; K Iqbal
Journal:  J Neural Transm (Vienna)       Date:  2004-10-27       Impact factor: 3.575

6.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

7.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Authors:  Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Tero Tapiola; Hiroyuki Arai; Kaj Blennow; Niels Andreasen; Klaus Hofmann-Kiefer; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Russell Kohnken; Frank Padberg; Tuula Pirttilä; Marc B Schapiro; Stanley I Rapoport; Hans-Jürgen Möller; Peter Davies; Harald Hampel
Journal:  Arch Neurol       Date:  2002-08

8.  Phosphorylation of tau protein to sites found in Alzheimer's disease brain is catalyzed by Ca2+/calmodulin-dependent protein kinase II as demonstrated tandem mass spectrometry.

Authors:  Yoshiyuki Yoshimura; Tatsuya Ichinose; Takashi Yamauchi
Journal:  Neurosci Lett       Date:  2003-12-26       Impact factor: 3.046

9.  CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.

Authors:  Hideki Shimura; Daniel Schwartz; Steven P Gygi; Kenneth S Kosik
Journal:  J Biol Chem       Date:  2003-11-10       Impact factor: 5.157

10.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Authors:  K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

View more
  9 in total

1.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

2.  Identification of novel candidate genes for Alzheimer's disease by autozygosity mapping using genome wide SNP data.

Authors:  Richard Sherva; Clinton T Baldwin; Rivka Inzelberg; Badri Vardarajan; L Adrienne Cupples; Kathryn Lunetta; Abdalla Bowirrat; Adam Naj; Margaret Pericak-Vance; Robert P Friedland; Lindsay A Farrer
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Polyubiquitin Profile in Down Syndrome and Alzheimer's Disease Brain.

Authors:  Antonella Tramutola; Marzia Perluigi
Journal:  Methods Mol Biol       Date:  2021

4.  Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.

Authors:  Dolores Del Prete; Richard C Rice; Anjali M Rajadhyaksha; Luciano D'Adamio
Journal:  J Biol Chem       Date:  2016-06-20       Impact factor: 5.157

5.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

Review 6.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

7.  Refined phosphopeptide enrichment by phosphate additive and the analysis of human brain phosphoproteome.

Authors:  Haiyan Tan; Zhiping Wu; Hong Wang; Bing Bai; Yuxin Li; Xusheng Wang; Bo Zhai; Thomas G Beach; Junmin Peng
Journal:  Proteomics       Date:  2014-12-15       Impact factor: 3.984

8.  Current status of the plant phosphorylation site database PhosPhAt and its use as a resource for molecular plant physiology.

Authors:  Borjana Arsova; Waltraud X Schulze
Journal:  Front Plant Sci       Date:  2012-06-19       Impact factor: 5.753

9.  Histone post-translational modifications in frontal cortex from human donors with Alzheimer's disease.

Authors:  Kyle W Anderson; Illarion V Turko
Journal:  Clin Proteomics       Date:  2015-10-01       Impact factor: 3.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.